drugset / Trial / NCT02456363
Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis
RandomizedParallel-groupOpen-labelTreatment
Summary
Assessed using (1) Adalimumab(Humira) and NSAIDs (2) Use only Adalimumab(Humira) treatment of ankylosing spondylitis patient safety and efficacy.
Timeline
- Start
- 2009-11
- Primary completion
- 2019-10
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | — | — |
| Subject | Etanercept | Protein / enzyme biologic | — | — |
| Subject | Golimumab | Monoclonal antibody | — | — |
| Subject | Sulfasalazine | Small molecule | — | — |
| Background | Celecoxib | Other / unclassified | — | — |
| Background | Etoricoxib | Small molecule | — | — |
| Background | Meloxicam | Small molecule | — | — |
| Background | Tonec | Unknown | — | — |